ストックスクリーナーアプリを入手
36.23
0.08%
0.03
前日終値:
$36.20
開ける：
$36.39
24時間の取引高:
1.55M
Relative Volume:
1.05
時価総額：
$3.50B
収益：
$610.16M
当期純損益:
$-532.93M
株価収益率:
-6.5531
EPS:
-5.5287
ネットキャッシュフロー:
$-442.30M
1週間 パフォーマンス:
-0.41%
1か月 パフォーマンス:
+8.05%
6か月 パフォーマンス:
-7.79%
1年 パフォーマンス:
-22.73%
1日の値動き範囲:
$35.93
$36.54
1週間の範囲:
$35.65
$39.89
52週間の値動き範囲:
$25.81
$47.12
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
RARE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
36.23 | 3.49B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 3,081 Shares - MarketBeat
Ultragenyx (RARE) CFO Horn sells $112k in stock By Investing.com - Investing.com Canada
Ultragenyx (RARE) CFO Horn sells $112k in stock - Investing.com
Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Bank of Nova Scotia Purchases Shares of 241,985 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Norges Bank Invests $35.77 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Holdings Boosted by Hsbc Holdings PLC - MarketBeat
Is Ultragenyx Pharmaceutical Inc. stock near bottom after declineJuly 2025 Recap & Safe Investment Capital Preservation Plans - Newser
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Sands Capital Management LLC - MarketBeat
Schroder Investment Management Group Acquires 71,888 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock attract long term capital inflowsLong Setup & Expert Verified Movement Alerts - Newser
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight - Yahoo Finance Singapore
RARE: Phase 3 data in rare diseases and gene therapy filings are set to drive growth this year - TradingView
Skandinaviska Enskilda Banken AB publ Has $2.46 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Capital Fund Management S.A. Buys 43,903 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 03 - marketscreener.com
Loomis Sayles & Co. L P Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly resultsJuly 2025 Breakouts & Daily Volume Surge Signals - Newser
Legal & General Group Plc Purchases 54,837 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock hit Wall Street targets2025 Valuation Update & Precise Buy Zone Tips - Newser
Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest - Yahoo Finance
Ultragenyx Shares Rally After FDA Updates Are They Priced Right for 2025? - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook - Sahm
Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook - MSN
Ultragenyx to Participate in Investor Conferences in December - Sahm
Rhenman & Partners Asset Management AB Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bear Alert: Will Ultragenyx Pharmaceutical Inc. stock see PE expansion2025 Earnings Surprises & Low Risk Entry Point Tips - BỘ NỘI VỤ
Is Ultragenyx Pharmaceutical Inc. stock positioned well for digital economyTake Profit & Accurate Entry/Exit Alerts - moha.gov.vn
Why Ultragenyx Pharmaceutical Inc. stock is favored by top institutionsNew Guidance & Daily Chart Pattern Signal Reports - moha.gov.vn
Barclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $3.28 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Geode Capital Management LLC - MarketBeat
Barclays Maintains Ultragenyx Pharmaceutical (RARE) Overweight Recommendation - Nasdaq
Ultragenyx (NASDAQ: RARE) to join Citi, Evercore healthcare investor conferences - Stock Titan
RARE: Barclays Lowers Price Target Amid Maintaining Overweight R - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Pharma stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Australia
Is Ultragenyx Pharmaceutical Inc. (UP0) stock a defensive play amid uncertaintyPortfolio Update Report & AI Enhanced Execution Alerts - newser.com
Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect - Seeking Alpha
Will Ultragenyx Pharmaceutical Inc. stock reach all time highs in 20252025 AllTime Highs & Growth Focused Entry Reports - newser.com
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):